Drug intelligence / Profile preview

oral sulfate solution + linaclotide

Development stage: Approved
Lead developer: Ironwood Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Oral sulfate solution (OSS) + linaclotide is a combination bowel cleansing regimen used primarily for patients with chronic constipation undergoing colonoscopy. Linaclotide is a guanylate cyclase-C agonist that increases intestinal fluid secretion, which helps ease the passage of stools and relieve constipation symptoms. When combined with oral sulfate solution, this regimen aims to improve bowel preparation quality in patients with chronic constipation, who often experience inadequate bowel preparation for colonoscopy procedures.

Other names: OSS + linaclotidelinaclotide and OSS

Targets

GUCY2C (Guanylate cyclase C receptor)

Beyond the preview

Go deeper on oral sulfate solution + linaclotide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on oral sulfate solution + linaclotide.

Explore the full profile